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An  experimental  form  of  hepatic  porphyria  which  biochemically  resembles  the 
genetic disease of man, acute intermittent porphyria (1, 2), can be induced readily in 
rats by the administration of allylisopropylacetamide (AIA),  1 a chemical agent struc- 
turally related to Sedormid (3, 4). The increase in urinary output of &aminolevulinic 
acid (ALA) and porphobilinogen (PBG) and the hepatic accumulation of porphyrins 
that  result  from  treatment  with  this  agent  are  due  to  the  induction  of hepatic  ~- 
aminolevulinate  synthetase  (ALAS)  (5),  the initial  and rate-limiting  enzyme in the 
biosynthesis of porphyrins and heine (6, 7). 
The production of experimental porphyria in rats with AIA is accompanied by a 
concomitant hypertrophy of the liver (8) which can be accounted for almost entirely 
by an increase in the volume of hepatocytes (9). Ultrastructural studies of the liver in 
AIA-treated rats have revealed substantial  proliferation of the smooth endoplasmic 
reticulum (SER), enlargement of various intracellular organelles,  and accumulation of 
lipid droplets in the hepatocytes (9-11). 
During  the  course  of  studies  on  drug-induced  experimental  porphyria  in 
animals, we noted that neonatal rats were refractory to the porphyria-inducing 
properties of various drugs and chemicals including the potent ALAS-inducing 
agent,  AIA  (12,  13).  The  observation  prompted  the  present  study,  which  is 
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1Abbreviations used in this paper: AIA, allylisopropylacetamide;  ALA,  ~-aminolevulinic 
acid; ALAS, ~-aminolevulinate synthetase;  DDC, diethoxycarbonyl  dihydrocollidine; PBG, 
porphobilinogen; SER, smooth endoplasmic reticulum. 
THE  JOURNAL OF  EXPERIMENTAL MEDICINE • VOLUME 134,  1971  1349 1350  POSTNATAL  DEVELOPMENT  AND  EXPERIMENTAL  PORPHYRIA 
concerned with  the biochemical and morphological alterations in the livers of 
AIA-treated rats during various stages of postnatal development. The occurence 
of developmental changes in the inducibility of hepatic ALAS which we report 
here  also  provided  us with  a  unique  opportunity  to  examine  the  relationship 
between  ALAS  activity in liver cells  and  the  drug-mediated  induction  of  the 
hepatic hemoprotein,  cytochrome P-450. 
Materials and Methods 
Animals.--Female  Sprague-Dawley rats (Charles River Laboratories, Wilmington, Mass.) 
were obtained on the 16th day of pregnancy and housed singly in cages free of softwood bed- 
ding (14). The times of birth of the neonates were carefully  noted for each pregnant female, 
and the neonates were allowed free access to maternal milk after birth.  The age of each liter 
of neonates was determined with an accuracy of 4-12 hr. 
On the day before experiments, the neonates were removed from their mothers and fasted 
for various periods up to 24 hr. Drugs and chemicals were administered intraperitoneally. The 
neonates were studied for induction of hepatic ALAS at 5-day intervals from birth until 20 
days of age and at 10-day intervals thereafter until 40 days of age. Fetuses were examined for 
response to AIA in utero by administering the chemical to pregnant rats 5 days before the date 
of expected delivery. For the microsomal cytochrome P-450, the neonates were examined at 
ages 3, 6,  10, and 30 days. Female rats weighing 100-200 g were used as adults in all experi- 
ments. 
Drugs and Chemlcals.--Phenobarbital (100 mg/kg) and AIA (400 mg/kg) were administered 
as aqueous solutions of 0.85%  NaC1.  Diethoxycarbonyl dihydrocollidine (DDC) 2 (250 rag/ 
kg) was administered as a solution ill propylene glycol. ALA (30-120 moles/100 g) was given 
as a  solution in 0.85% NaC1. 
Enzyme Assay.--ALAS  was  assayed  in  liver homogenates according  to  the  method  of 
Marver et at. (15). Some reaction mixtures for this enzyme assay contained succinyl coenzyme 
A synthesized according to the method of Simon and Shemin (16). ALA and amino acetone, 
synthesized in the reaction mixtures, were separated and determined by solvent extraction as 
described by Granick (7). The unit of ALAS activity was expressed as millimicromoles ALA 
formed per hour per gram liver. 
Determination of Microsomal Cytochrome.--Cytochrome P-450 was quantitated in dithio- 
nite-reduced preparations of liver microsomal fractions by its carbon monoxide difference 
spectrum as determined in a Cary 15 spectrophotometer (Cary Instruments, Monrovia, Calif.) 
according to the method of Omura and Sato (17). Incorporation of ALA-3,5-3H and glycine- 
2-~*C (New England Nuclear Corp., Boston, Mass.) into microsomal cytochrome P-450 was 
carried out as follows: 50 ~zCi/100 g of ALA-3,5-3H  or 30 #Ci/100 g of glycine-2-14C  was in- 
jected intraperitoneally and the rats sacrificed 3 hr later. Microsomal preparations from their 
livers were then converted to carbon monoxide-binding particles by digestion with 0.3% (w/v) 
crude pancreatic lipase (Steapsin, Nutritional Biochemicals Corporation, Cleveland, Ohio), as 
described by Omura and Sato (17). The resulting preparations, containing 80-95% of original 
cytochrome P450 in the form of cytochrome P-420 (18) and virtually free of cytochrmne b5, 
were counted in a Beckman LS-250 Liquid Scintillation System (Beckman Instruments, Inc., 
Fullerton, Calif.) as in the method of Levin and Kuntzman (19). 
Cytochrome b5 was determined from the difference spectrum between nicotinanfide adenine 
dinucleotide (reduced form)- (NADH)-reduced and air-saturated suspensions of microsomes 
(18). In some preparations of microsomal fractions as well as of CO-binding particles, NADH- 
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cytochrome b5 reductase, purified according to Takesue and Omura (20), was added to ensure 
complete reduction of cytochrome bs. Protein was measured according to the method of Lowry 
et al. (21). 
Porph~rir~  Deterraination.--Porphyrin  content  of  the  liver  was  determined  spectro- 
fluorometrically as follows.  Homogenates of livers were prepared in distilled water and small 
aliquots, containing approximately 10 mg of protein, were freeze-dried. Porphyrins from the 
lyophilates were then extracted with a solvent containing equal volumes of  N-perchloric acid 
and absolute methanol (Spectral Grade, Matheson Coleman & Bell, Matheson Co., Inc., East 
Rutherford, N. J.). After titration through Whatman No. 2 filter paper, fluorescence emission 
spectra of porphyrins contained in the solvent were traced in a  Hitachi-Perkin-Elmer MPF- 
2A fluorescence spectrophotometer (Hitachi, Ltd., Tokyo, Japan; Perkin-Elmer Corp. Instru- 
ment Div., Norwalk, Conn.) (22). 
Bilirubin  Determination.--Serurn  bilirubin was  measured  by  coupling  with  diazotized 
sulfanilic acid (23). 
Electron Microscopic Studies.--Livers from 27 animals were examined in the electron micro- 
scope 16 hr after administration of 0.85% NaCI solution (9 animals), phenobarbital (9 animals), 
and AIA (9 animals). With the exception of 3 adult animals (1 control and 2 AIA-treated), the 
remaining animals were  5  or  7  days old. 
The liver specimens were cubed into 1 mm blocks and fixed in 3% (w/v) glutaraldehyde in 
a  modified Tyrode's solution (pH  7.2)  for 3 hr  (24),  rinsed in 7.5%  (w/v) sucrose solution 
buffered with 0.01 M phosphate buffer (pH 7.2), and then postfixed in Millonig's osmic acid 
fixative (25). Mter dehydration in graded ethanol solutions, tissue blocks were passed through 
propylene oxide and embedded in Maraglas (Polysciences, Inc., Rydal, Pa.). Mid-zonal areas 
of the hepatic lobule were selected for thin sectioning from 1-/z-thick sections after examination 
by phase-contrast microscopy. Thin sections stained with uranyl acetate and lead citrate were 
examined in a  Philips EM  300  electron microscope  (Philips Electronic  Instruments,  Mr. 
Vernon, N. Y.). 
RESULTS 
Induction of Hepatic ALAS.--There was a progressive increase in the activity 
of hepatic ALAS after a single administration of AIA to adult rats. The activity 
reached a peak level,  approximately  12 times the control values, by 12-16 hr 
after the administration of the chemical (Fig. 1). Fig. 1 also shows the response 
of hepatic ALAS activity after a single injection of an equivalent dose of AIA 
to neonatal rats. No induction of ALAS of a magnitude comparable to that seen 
in adult rats was noted. The mean value of ALAS activity did approximately 
double (P  <  0.01)  by the 9th hr after AIA. No further increase in ALAS ac- 
tivity was noted during an observation period of up to 30 hr after injection of 
the inducing agent. 
Fig. 2 illustrates the response to AIA in rats during various perinatal and de- 
velopmental stages.  An essentially complete lack of full responsiveness  to the 
induction of hepatic ALAS characterized the fetuses and the newborn animals, 
despite the great potency of AIA for induction of this enzyme in adult rats. This 
refractoriness lasted until about 10 days of age. Some induction was seen by 15 
days of age,  and the inducibility of hepatic ALAS  rapidly increased thereafter 
during weaning, approaching adult levels with further physical maturation. 1352  POSTNATAL  DEVELOPMENT  AND  EXPERIMENTAL  PORPtIYRIA 
Of interest were the observations on the basal hepatic ALAS activity in the 
immediate perinatal periods  (Fig. 2). The ALAS activities in fetal rats 5 days 
before delivery were significantly higher than those noted during later periods 
in development. The mean activity of ALAS in the fetal liver was 55 m#moles/ 
hr per g. The activity progressively declined after delivery to reach one third of 
this level by the 15th day. Similar observations on hepatic ALAS activities  of 
fetal  rats,  guinea  pigs,  and  rabbits  have  recently been  made  by Woods and 
Dixon (26). 
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FIG. I.  Time course of induction of ALAS in adult and neonatal rats by AIA. 30  adult 
female rats weighing 130-140 g and 40 7-day-old rats were starved for 24 hr before administra- 
tion of AIA (400 mg/kg) intraperitoneally.  Rats were killed in groups of 3-5  at indicated 
intervals and hepatic ALAS activity was determined in each liver. Each point represents the 
mean value of ALAS activity 4- one standard deviation. 
Fig. 3 shows the refractoriness of neonates to the induction of ALAS by pheno- 
barbital, a  drug which  caused an approximately four-fold increase  in hepatic 
ALAS activity in adult rats. No statistically significant  increase  in ALAS ac- 
tivity was noted in neonates treated with phenobarbital. The newborn rats were 
also refractory to the induction of ALAS by DDC, an extremely potent  por- 
phyria-inducing chemical known to induce readily this enzyme in adult animals 
(6) and other experimental preparations (7). 
The following manipulations had no influence on the neonatal refractoriness 
to drug induction of hepatic ALAS: (a) variations of substrate  concentrations 
in the enzyme assay, (b) variations of the interval between drug administration 
and the enzyme assay, (c)  addition of succinyl coenzyme A  to the ALAS reac- SONG,  MOSES,  ROSENTHAL,  GELB~  AND  KAPPAS  1353 
tion mixture, (d) administration of glucocorticoids to the newborn animals, and 
(e)  withdrawal of the neonates from maternal milk or feeding on an  artificial 
formula  3 for 60-72 hr. Moreover, unlike adult animals, in whom fasting enhances 
the degree of ALAS induction by drugs (27), the ALAS activities in fasted and 
nonfasted neonates did not differ significantly. 
The  absence of possible inhibitors of ALAS in neonatal livers (28)  was  as- 
certained by addition experiments in which varying amounts  of homogenates 
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FIG. 2.  Relation between perinatal development and induction of hepatic ALAS by AIA. 
5-10 rats of indicated age before and after birth were starved for 24 hr and given AIA (400 
mg/kg) intraperitoneally. Adult rats were mature virgin female rats weighing 150-200 g. 16 
hr after AIA, the animals were killed and hepatic ALAS activity was determined in each liver. 
Each point represents the mean value of ALAS activity +  one standard deviation. 
of neonatal liver were added to ALAS reaction mixtures containing adult liver 
homogenates with high ALAS activities. The latter activities were not inhibited 
by  the  neonatal  homogenates.  The  gestational hormones,  estradiol and  pro- 
gesterone, to which  the neonates may have been exposed, did not inhibit the 
drug induction of ALAS in adult animals when they were pretreated with these 
hormones,  4 both singly and in combination, for 7 days. 
Artificial  formula was prepared as follows: 60 g egg yolk, 60 g dry milk, 90 g corn oil, 6 g 
casein, 6 g commercial vitamin mixture for rats, 6 g choline, and 372 g distilled water to make 
600 g of formula. 
4 Estradiol (1 mg) or progesterone  (10 mg) in 0.5 ml propylene glycol administered sub- 
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Changes in  Liver  Weight  after the  Administration  of AIA.--A  substantial 
enlargement of liver weight is a  well-known concomitant of the hepatic por- 
phyria produced by AIA in adult rats (9, 27). As shown in Table I, a greater 
than 100 %  average increase  in liver weight  was noted  in adult  rats  approxi- 
mately 16 hr after a  single administration of AIA. In contrast,  no significant 
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FIG.  3.  Time course of induction of ALAS in adult and neonatal rats by phenobarbital. 
30 adult female rats weighing about 100 g and 20 5-day-old rats were starved for 16 hr before 
administration of AIA  (400 mg/kg)  intraperitoneally.  Rats were killed  in groups of 4-5  at 
indicated intervals and hepatic ALAS activity was determined in each liver. Each point repre- 
sents the mean value of ALAS activity -4- one standard deviation. 
TABLE  I 
Mean  Liver  Weights in Rats of Various Ages  Treated  With AIA* 
Age  Control  AIA  Change in liver weight 
g _-t: standard  error  g ::i: slandard  error  % 
5 days  0.21  -4- 0.02  (11)  0.19  -¢- 0.01  (10)  Not significant 
20 days  1.20  +  0.11  (9)  1.50  q- 0.05  (9)  +25  (P  =  0.025) 
Adults~  2.04  4- 0.23  (8)  4.11  -4- 0.21  (8)  +103  (P  <  0.005) 
* All  animals were  fasted  24  hr  before  AIA administration.  Liver weights were  deter- 
mined 16 hr after AIA. Figures in parentheses indicate number of animals. 
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FIG. 4.  Induction of microsomal cytochrome P-450 by phenobarbital in developing rats. 
Animals of indicated age were starved for 16 hr and divided into 3 groups: the "saline" group 
received 0.85~o  NaC1 intraperitoneally; the  "phenobarbital" group  received  100 mg/kg  of 
phenobarbital in 0.85% NaC1 intraperitoneally; the "phenobarbital +  ALA" group received, 
in addition to phenobarbital, 120 #moles of ALA in 0.85% NaC1 intraperitoneally in three 
divided doses, the first dose immediately after, the second and  third  at  4  and  8  hr  after, 
phenobarbital treatment. Each group of animals was killed 24 hr later,  livers were  pooled, 
and the microsomal fractions isolated. Cytochrome P450 was determined in each pooled prep- 
aration of liver microsomes. The number of animals ranged from 5 adults (100-150 g)  to  18 
for the  neonates. 
TABLE  II 
Incorporation  of Glyclne-2-14C and  ALA-3,5-aH  into  Carbon Monoxide-Binding  Particles 
of Neonatal Rat Liver* 
ALA-3,5-3H  Glycine-2J4C 
cpm/g liver  cpm/g liver 
Control  6088  (17)  6404  (15) 
Phenobarbital-treated  19,869  (14)  11,838  (16) 
* 5-day-old  (ALA-3,5-3H)  and  7-day-old  (glycine-2-14C)  rats  were  given  the  labeled 
precursors intraperitoneally  16 hr after  treatment with saline  (control)  or  phenobarbital. 
The rats were killed 3 hr later and livers were pooled and carbon monoxide-binding particles 
isolated from pooled livers as described. Figures in parentheses indicate the number of ani- 
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change in liver weight was detectable in AIA-treated neonatal rats of 5 days of 
age.  By 20  days of  age,  however,  at which  time a  significant AIA-mediated 
induction of hepatic ALAS was detectable  (Fig. 2),  a  smaller (25%)  but sig- 
nificant increase in liver weight was apparent in the developing animals. 
Relationship  3etween Induction of Hepatic ALAS and Microsomal Cytochrome 
P-450.--ALAS is the rate-limiting enzyme in the hepatic biosynthesis of por- 
phyrins and heine (6, 7); it has therefore been suggested that the induction of 
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FIG. 5.  Fluorescence emission spectra of porphyrins isolated from livers of neonatal rat. 
treated with phenobarbital and phenobarbital plus ALA. Three groups of 17-18 rats of 5 days 
of age were treated with 0.85% NaC1, phenobarbital (100 mg/kg in 0.85% NaC1), and pheno- 
barbital plus ALA (90 #moles/100 g in 0.85% NaC1). ALA was administered in three divided 
doses as indicated in the legend for Fig. 4. Each group of animals was killed 24 hr later and the 
homogenates from  the pooled livers were lyophilized and extracted  with  perchloric acid- 
methanol solvent. The fluorescence  emission spectrum was traced for each solvent at identical 
sensitivity setting. A represents tracings for saline- and phenobarbital-treated groups, showing 
no porphyrin fluorescence; B represents a tracing for  the phenobarbital  plus  ALA-treated 
group. The emission spectrum is similar to that obtained for the protoporphyrin IX standard, 
curve C. SONG,  MOSES,  ROSENTHAL,  GELB,  AND  KAPPAS  1357 
this  enzyme,  which  would  then  lead  to  an  increase  in  availability  of heine, 
might be a  necessary event preceding  the increase  in the hepatic microsomal 
hemoprotein,  cytochrome P-450,  which is brought about by exposure  of ani- 
mals  to  drugs  such  as  phenobarbital  (29).  This  relationship  between  ALAS 
activity and cytochrome P-450 of the liver was examined in neonatal and de- 
veloping rats (Fig. 4) by quantitating the hemoprotein level after treatment of 
the animals with phenobarbital. Untreated newborn rats had very little P-450 
in the liver, amounting to about one third of the level present in adult hepatic 
microsomes when  expressed  in terms  of microsomal  protein,  Despite  the  re- 
fractoriness  of the  neonates  to induction  of hepatic  ALAS by phenobarbital, 
TABLE III 
Serum Total Bilirubin in Neonatal Rats Treated with ALA * 
No. of animals  Total bilirubin 
Control  (17) 
Phenobarbital  (18) 
Phenobarbital  plus: 
120/zmoles/100 g ALA  (18) 
90/zmoles/100 g ALA  (18) 
60/zmoles/100 g ALA  (18) 
30/zmoles/100  g ALA  (18) 
120/zmoles/100 g ALA  (17) 
(mg/lO0 ml) 
0.4 
0.1 
4.3 
1.4 
1.7 
0.6 
11.3 
* 5-6-day-old rats weighing 11-15 g were used. Control  animals received 0.1-0.15 ml of 
0.85%  NaCI.  Phenobarbital  was given intraperitoneally  at  100 mg/kg. ALA was admin- 
istered  intraperitoneally  in  three  divided  doses at  4-hr  intervals,  beginning  immediately 
after  the phenobarbital  treatment.  All animals sacrificed by decapitation  24 hr later. Blood 
from animals in each group was pooled and the bilirubin concentration  in the pooled sera 
was determined. 
an increase in microsomal cytochrome P-450 of the liver mediated by this drug 
was demonstrable  throughout the neonatal period  (Fig. 4). A  more than  two- 
fold increase in this cytochrome was noted as early as 3 days after birth  after 
treatment with phenobarbital,  although the drug-stimulated  level of P-450 at 
that age was still substantially less than the P-450 level in the microsomal frac- 
tions  of  untreated  adult  rat  livers  (Fig.  4).  Phenobarbital-treated  neonates 
also  incorporated  the  heine  precursors,  ALA  and  glycine,  into  microsomal 
cytochrome P-450 at rates significantly increased over those of untreated litter 
mates (Table II). 
Effect  of  ALA  on  Phenobarbital-Mediated  Induction  of  Microsomal  Cyto- 
chrome P-450.--To examine further the relationship between hepatic ALAS and 
the  degree  of  phenobarbital-stimulated  induction  of  cytochrome  P-450,  the 
rate of the ALAS step was arbitrarily increased in the liver by exogenous ad- 1358  POSTNATAL  DEVELOPMENT  AND  EXPERIMENTAL  PORPHYRIA 
ministration  of the  product  of  this  enzymic reaction,  ALA.  Treatment  with 
various doses of ALA up to 30/zmoles/100 g of body weight,  administered in 
3-4 divided doses during the 24 hr after exposure to phenobarbital, had no in- 
fluence on the drug-mediated increase in cytochrome P-450  of neonatal  rats. 
When it was given in doses in excess of 60 ~moles/100 g, however, the ALA in 
fact blocked  the  drug-induction  of P-450  in  the  microsomal fractions  of  the 
neonates (Fig. 4). 
Hepatic uptake  and  conversion  of  the  exogenous  ALA  to porphyrins  and 
heme was established by the following observations. First, after the administra- 
tion  of  ALA,  there  was  a  progressive  and  large  increase  in  the  amount  of 
porphyrins found in liver cells (mostly in the form of protoporphyrin IX)  as 
shown  by  the  representative  fluorescence  emission  spectra  of  liver  extracts 
depicted in Fig. 5. Second,  the conversion of this protoporphyrin IX to heme 
was demonstrated by the rapid appearance of hyperbilibubinemia and jaundice 
in the ALA-treated neonates (Table III). This hyperbilirubinemia, which was 
an unexpected finding,  implies the presence of a  protoporphyrin IX-to-heme 
conversion catalyzed by ferrochelatase  ~ and then  a  heme-to-bilirubin conver- 
sion catalyzed by the heme oxygenase (30, 31) in the livers of the neonatal ani- 
mals. Protoporphyrin IX itself is not a substrate for heme oxygenase (31). 
Electron Microscopic Observations.--The  electron microscopic appearance of 
a hepatic parenchymal cell from an adult rat treated with 0.85 % NaC1 solution 
is illustrated  in  Fig.  6.  Fasting  for the 40 hr experimental period resulted in 
depletion of a  major portion  of the visible glycogen rosettes;  no other ultra- 
structural changes were noted. 
Fig. 7 depicts a  representative hepatocyte from the liver of an adult rat 16 
hr after a single dose of AIA. The hepatocytes were hypertrophied because of 
an increase  in  both  the  nucleus  and  cytoplasm;  the  nucleoli were markedly 
enlarged with the increase disproportionately greater than that of the total cell. 
The most  striking  morphologic  change  noted  was  a  marked  proliferation  of 
SER  membranes so  that  masses  composed ahnost  exclusively of  SER  were 
prominent within the cytoplasm. The cisternae of the hypertrophied SER had 
a  more regular diameter than those of controls and thus  appeared tubular in 
nature.  Golgi-associated vesicles of porphyric livers contained dense lipid-like 
material, and apparent lipoprotein granules were present within SER cisternae 
as well as in the Golgi vesicles. There was also a patchy accumulation of large 
lipid  vacuoles  within  the  cytoplasm,  usually  within  or  adjacent  to  areas  of 
hypertrophied SER.  These hepatocellular alterations  were entirely similar to 
5 In a preliminary study, the presence of ferrochelatase activity (32) was demonstrated in 
the liver homogenates of the newborn rats. In 5-day-old rats, the activity of this enzyme was 
approximately 50% of that noted in the adult rats weighing 100 g, when expressed in terms of 
wet weight of the liver. Fro. 6.  Adult liver, control. Hepatocyte from an adult rat treated with 0.85% NaC1 solu- 
tion. Note the relatively small nucleolus (NL)  and the Golgi apparatus  (G)  containing  small 
granules of medium density. Small islands of SER (S)  are present. )< 15,000. 
Fro. 7.  Adult liver, AIA effect.  Hepatocyte  from an adult rat  treated with AIA  16 hr 
before sacrifice.  Note the prominent enlargement of the nucleolus (NL) and the large cyto- 
plasmic masses of hypertrophied SER  (S). Lipid vacuole (L).  X  15,000. 
1359 FIO. 8.  Neonatal liver, control. Parenchymal cells of neonatal animals were much smaller 
than those of adult animals and contained prominent nucleoli. Neonatal liver ceils generally 
contained relatively small quantities of rough-surfaced endoplasmic reticulum and very scant 
SER.  The Golgi apparatus  (G) and associated vesicles very frequently contained numerous 
lipoprotein-like granules  (40-60 m~z in diameter)  of high density.  A  bile  canaliculus  (BC). 
X  15,000. 
Fro. 9.  Neonatal liver, AIA effect. No morphologic changes attributable to AIA treatment 
were detected in neonatal hepatocytes.  X  15,000. 
1360 FIG. 10.  Neonatal liver, phenobarbital effect. Livers of neonatal rats treated with pheno- 
barbital occasionally showed greater development  of SER (S) than was observed in any of the 
control animals. Tubular hypertrophy of the SER as seen in hepatocytes of adult rats treated 
with phenobarbital was not observed in the neonatal animals. The Golgi apparatus (G) and 
associated vesicles showed a relative depletion of lipoprotein-like granules. X  15,000. 
FIG. 11.  Same as Fig. 10. This higher magnification of the SER shows connections  between 
the smooth and the rough-surfaced endoplasmic reticulum. Many membrane-bound and un- 
bound polysomes are present. A bile canaliculus (BC). X  30,000. 
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those previously described in detail in rats treated with the porphyria-inducing 
agent, AIA (9). 
The parenchymal cells of neonatal livers had an ultrastructural appearance 
different from that of adult livers, and the neonatal liver cells responded dif- 
ferently to AIA administration. The neonatal cells were smaller in size, with a 
higher nucleo-cytoplasmic ratio. There was less rough endoplasmic reticulum 
in the cytoplasm. Particularly striking was the paucity of SER (Fig. 8). Rela- 
tive  to  the  other  cytoplasmic  components,  the  Golgi  apparatus  appeared 
especially well developed and contained numerous lipoprotein-like granules of 
high density. 
Administration  of  AIA  to  neonatal  rats  utilizing  the  same  experimental 
conditions which induced pronounced morphological changes in adult rat livers 
produced no detectable structural alterations (Fig. 9). Livers from the 7 AIA- 
treated neonatal rats appeared identical in all respects with those of untreated 
litter mates. 
Of the livers from 9 neonatal rats treated with phenobarbital, 3 demonstrated 
development of the SER in excess of that observed in any of the 8 untreated 
litter mates (Figs. 10 and 11). This increase in SER was patchy, involving some 
hepatocytes but not others in a  given section; however, the livers of pheno- 
barbital-treated neonates exhibited no tubular hypertrophy of the SER such as 
that observed in adult animals treated with phenobarbital (33). Golgi-associated 
vesicles appeared  to contain fewer lipoprotein-like granules  than were noted 
in untreated litter mates. 
DISCUSSION 
Drug induction  of hepatic ALAS and the production  of experimental  hepatic 
porphyria in animals can be modified by a number of nutritional, endocrine, 
genetic, and other factors. Thus, starvation before the administration of por- 
phyrinogenic drugs or chemicals enhances the induction of ALAS (27), while 
feeding or the administration of glucose  diminishes or abolishes this drug effect 
(3, 27). Glucocorficoid  hormones  have  a permissive  effect  on the drug induction 
of ALAS (34), i.e., adrenalectomy  abolishes the drug effect,  which can be re- 
stored by subsequent replacement  of the glucocorticoid  hormone, hydrocorti- 
sone. Administration of heme, the end product of the porphyrin-heme  pathway, 
also abolishes the drug induction of ALAS (29, 35), an effect  that has been at- 
tributed to the role  of heine as a corepressor  agent in the regulation of ALAS 
synthesis in liver cells (7, 36). Heine also inhibits the apparent incorporation  of 
ALAS found  in the soluble fraction of liver cells into the mitochondria after 
drug induction of this enzyme (37). Ferric citrate has a marked synergistic 
effect in the induction of ALAS (38). Finally, genetic factors have recently 
been invoked to explain differences  in the degree of inducibility of ALAS in 
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the developmental stage of animals which, as shown in the present study, also 
have a profound effect on the drug induction of hepatic ALAS. 
The perinatal period of the mammal is generally characterized by a lack in 
many tissues of the full enzymatic constitution of the adult (40, 41),  and the 
process  of  parturition  or  the  physical  development  after  birth  correlates 
specifically with the appearance or the increase in activity of a number of hepa- 
tic  enzymes. Those  hepatic  enzymes which  show  increases  in  their  specific 
activity during certain stages in the postnatal period include histidase (42), 
acetyl  coenzyme  A  carboxylase  (43),  tyrosine  aminotransferase  (44,  45), 
tryptophan oxygenase (46),  serine dehydratase (47),  uridine diphosphate glu- 
curonyl  (UDP-glucuronyl)  transferase  (48,  49),  certain  drug-metabolizing 
enzymes (50),  and others (51-61). 
The  induction  of  some  of  these  enzymes  which  accompanies  endocrine, 
nutritional, pharmacological, or other manipulations does not become apparent 
until after specific  stages in perinatal maturation have been reached. For ex- 
ample, the induction of hepatic tyrosine aminotransferase (45) and tryptophan 
oxygenase (46) by administration of hydrocorfisone or L-tryptophan in the rat 
is not possible until several days after birth or until about the 15th postnatal 
day, respectively. Various factors such as hormone secretion during puberty 
(42), dietary changes associated with weaning (43), and secretion of glucocorti- 
coid hormones and glucagon during perinatal periods (62, 63) have been pro- 
posed as underlying these alterations in hepatic enzyme activity and their in- 
ducibility by various agents. 
Our findings in this study suggest that the nutritional or endocrine altera- 
tions associated with physical maturation in the rat do not constitute the basis 
for the refractoriness of the neonates to the porphyrinogenic effects of various 
drugs and chemicals. Dietary and endocrine manipulations had no effect on the 
failure in the neonates of full induction of hepatic ALAS by drugs until the ap- 
proximate time of weaning. 
ALAS is localized in the mitochondria of hepatocytes (6, 64). The synthesis 
of this enzyme appears  to take place in the endoplasmic reticulum, and the 
enzyme accumulates transiently in the soluble fraction of the liver cells  (64). 
It is then incorporated into mitochondria. It is obvious that the induction of 
hepatic ALAS involves a  complex series  of events that include, in  the final 
stages, protein synthesis in the endoplasmic reticulum and subsequent transfer 
of  this  enzymic  protein  into  highly  specialized  subcellular  organelles,  the 
mitochondria.  Functional maturation  of  the  endoplasmic reticulum for  ex- 
pressing the genetic material for ALAS and of the mitochondria for incorpora- 
tion of the synthesized ALAS would be necessary before chemicals such as AIA 
could  manifest  their  full  pharmocological potential,  viz.,  excessive  hepatic 
synthesis of porphyrins and their precursors. Thus, an "immaturity" in one or 
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of mitochondrial ALAS would account for our findings. In this respect, it is of 
interest  that  enzymes  concerned with  the  mitochondrial  electron  transport 
system in the rat do not reach specific activities corresponding to those of adult 
animals until about 20-25 days after birth or until weaning (65, 66); however, 
an isolated defect of the neonatal liver mitochondria involving an inability to 
incorporate newly synthesized ALAS could not explain the low over-all activity 
of the enzyme in the livers of immature rats as noted in our experiments. 
The induction of ALAS by AIA in the rat is accompanied by an array of 
morphological  alterations  that  are  demonstratable  by  electron  microscopy. 
These include:  (a)  hypertrophy of hepatocytes,  (b)  volume enlargements  of 
cytoplasm, nucleus, and nucleoli of hepatocytes, (c) accumulation of lipoprotein- 
like granules within the cisternae of the SER, (d) formation of lipid droplets in 
the  cytoplasm,  and  (e)  proliferation of  the  SER  (9-11).  The mitochondria, 
however, show surprisingly little morphological change depsite the fact that the 
newly synthesized ALAS localizes in these structures. 
Some of the manipulations that have been shown to prevent the AIA-mediated 
induction of hepatic ALAS also prevent the morphological changes known to 
accompany the increase in the activity of this enzyme. Thus, in adrenalecto- 
mized rats  or rats  treated with  metabolic inhibitors such  as puromycin and 
actinomycin D, AIA fails to induce ALAS and does not produce the electron 
microscopic changes in the liver cells described above. Cultured rat hepatoma 
cells (67), which do not respond to AIA by induction of ALAS, also fail to de- 
velop these morphological alterations.  6 The present observations  in  neonatal 
rat livers are similar in that AIA produced neither an induction of ALAS nor 
nltrastructural changes in the hepatocytes. 
The association of the induction of ALAS with the morphological changes 
found in hepatocytes suggest that  these two seemingly disparate phenomena 
may be causally related in the production of experimental porphyria in the rat 
by AIA, although it is not possible at the present time to elucidate the basis of 
this relationship or the sequence in which the two phenomena take place. It is 
clear, however, that the AIA-mediated induction of ALAS is associated with 
alterations in biochemical pathways that are not directly involved in porphyrin- 
heme biosynthesis, and that such alterations, e.g. changes in the rates of syn- 
thesis of cholesterol and phospholipids (68), may find morphological expression 
in the ultrastructural changes observed in the liver cells. 
Cytochrome P-450, the hepatic hemoprotein that acts as the terminal oxy- 
genase in the microsomal mixed-function oxidase system (19, 69), can be induced 
by a  variety of steroids  as  well  as  drugs,  including  barbiturates,  polycyclic 
aromatic hydrocarbons, etc. (70, 71). The induction of P-450 is associated with 
increased activity of the liver for oxidative and, to a certain extent, reductive 
metabolism of many drugs, although this relationship is not strictly stoichio- 
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metric (72-74). Although heme is the prosthetic group for cytochrome P-450 
and is thus obviously required for the synthesis of this hemoprotein, it can also 
block the drug-mediated induction of P-450 when it is administered exogenously 
(75). 
We have shown in the present investigation that the phenobarbital-mediated 
induction  of microsomal cytochrome P-450 does  take place in neonatal rats 
despite the refractoriness of these animals to the effects of drugs which induce 
ALAS and would thus be expected to increase hepatic concentrations of por- 
phyrins and heine. The level of P-450 in the hepatocytes of the newborn rats is 
low,  with  a  corresponding scantiness  of  the  SER  demonstrable  by electron 
microscopy (Fig. 8). On a  single treatment with phenobarbital, however, the 
P-450 levels in neonatal livers more than doubled (Fig. 4) and islands of SER 
became discernible in some of the hepatocytes (Figs. 10 and 11). These findings 
are compatible with the recently described increases in hepatic rates of metabo- 
lism of aniline, ethylmorphine, and phenobarbital (76) in suckling rats exposed 
to phenobarbital. Our observations further indicate that the synthesis of P-450 
in the neonates appears to be under a regulatory control different from that of 
ALAS and that the basal production of ALA in the neonatal liver is sufficient 
to meet the heine requirements imposed by drug-induced increases in P-450 
synthesis. Increasing the hepatic concentration of ALA, porphyrins (Fig. 5), 
and presumably free heine by administration  of exogenous ALA to neonatal 
rats did not enhance the phenobarbital induction of P-450. Indeed, when the 
amount of administered ALA exceeded 60 ttmoles/100 g body weight, the in- 
duction of P-450 was actually blocked (Fig. 4)  and the neonatal animals de- 
veloped hyperbilirubinemia (Table III). Since bilirubin itself has no effect on 
the phenobarbital-mediated induction of P-450 (29), such an inhibitory effect 
of exogenous ALA must be due to its conversion to free heine in the liver and the 
action of this heme as a repressor of P-450 synthesis. It is not clear why this 
repressive effect of ALA was not observed in adult rats (Fig. 4). It is possible 
that there is a more rapid renal clearance of exogenous ALA in the adult ani- 
mals. 
Thus, the relationship between the activity of the porphyrin-heme biosyn- 
thetic pathway on the one hand and the rate of synthesis of cytochrome P-450 
on the other in the mammalian liver appears to be a complex one. In contrast 
to the hemopoietic system in which the enhancement of porphyrin and heine 
formation by the  induction  of ALAS  increases  the  rate  of synthesis  of  the 
hemoprotein, hemoglobin (77,  78), no such direct relation seems to hold in the 
liver at least as far as the formation of the hemoprotein, P-450, is concerned. 
Increasing the heme concentration in the liver by ALA administration, as evi- 
denced by the rapid  appearance of hyperbilirubinemia (Table III),  did not 
increase hepatic P-450 levels. Such manipulations in fact resulted in repressive 
effects on P-450 formation. This finding contrasts also with the case of another 
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the rat on treatment with AIA (79,  80)  as well as with ALA (81). There is no 
ready explanation for the paradoxical phenomenon in which free heine can on 
the one hand act as a prosthetic group and on the other act as an apparent re- 
pressor in the synthesis of cytochrome P-450. The presence within hepatocytes 
of more than one heine pool with distinct metabolic functions could explain these 
findings. Further studies concerning the existence of such functionally distinct 
heine pools, however, are hampered by the lack of sensitive means for quanti- 
tating free heine levels in biological materials. 
SUMMARY 
The  mitochondrial  enzyme ~-aminolevulinate  synthetase  (ALAS)  controls 
the rate-limiting step in the synthesis of porphyrins and heine. An experimental 
form of hepatic porphyria can be readily elicited in laboratory animals, such as 
the rat, by drugs and foreign chemicals which are known to enhance the de novo 
formation of this enzyme in the liver. 
The present study shows that there is a striking refractoriness to the induction 
of ALAS during the perinatal period in the rat. Chemicals which have potent 
porphyria-inducing activity in adult  animals have no significant inducing  ef- 
fect on hepatic ALAS in neonates. The ultrastructural changes which accompany 
the induction  of ALAS by drugs and chemicals in adult liver also fail to take 
place in the livers of neonates. A  progressive capacity  for  responding  to  the 
action of chemical inducers of hepatic ALAS does, however, develop in neonatal 
animals so that by approximately 5-6 wk of age experimental porphyria can be 
elicited as effectively in them as in adults. 
The  reasons  for  the  refractoriness  of  hepatic  ALAS  to  induction  in  the 
perinatal period are not known; but the findings of this study make it clear that 
ALAS belongs to that increasingly large group of liver enzymes in mammals 
whose  appearance,  increase  of  activity,  or  inducibility  is  developmentally 
determined. 
The occurrence of developmental changes in the indicibility of ALAS in the 
liver of neonates also provided an opportunity to study the relationship of this 
enzyme activity to  the drug-mediated  induction  of the  hepatic hemoprotein 
cytochrome P-450. This inducible hemoprotein serves as the terminal oxygenase 
in  the microsomal mixed-function oxidase system in the liver. The results  of 
this  study  indicate  that, in  contrast  to  the  refractoriness of ALAS to induc- 
tion, significant drug-induced changes of hepatic P-450 content  and of heine- 
precursor incorporation  into this cytochrome do take place in  neonates. The 
synthesis of P-450 thus appears to be under a regulatory control different from 
that of ALAS in neonates, and the relation between ALAS activity and P-450 
formation is not therefore a direct one. 
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